A mechanistic approach to understanding the factors affecting drug absorption: A review of fundamentals

Journal of Clinical Pharmacology

Volumn 42, Issue 6, 2002, Pages 620-643

  Martinez, Marilyn N ^a   Amidon, Gordon L ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ADRENALIN; ANTIARRHYTHMIC AGENT; ANTIHISTAMINIC AGENT; BACLOFEN; BETA LACTAM ANTIBIOTIC; CARRIER PROTEIN; CHOLESTEROL; CHOLINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE; FATTY ACID; FOSFOMYCIN; GABAPENTIN; GUANIDINE; LEVODOPA; METHOTREXATE; METHYLDOPA; NONSTEROID ANTIINFLAMMATORY AGENT; NUCLEOSIDE ANALOG; PACLITAXEL; PEPTIDE TRANSPORTER 1; PHOSPHONOACETIC ACID; PRAVASTATIN; PROTIRELIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SALICYLIC ACID; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; COTRANSPORTER; GLYCOPROTEIN P;

ARTICLE; CELL MEMBRANE TRANSPORT; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DIFFUSION; DRUG FORMULATION; DRUG METABOLISM; DRUG SOLUBILITY; DRUG TRANSPORT; FIRST PASS EFFECT; FOOD DRUG INTERACTION; HUMAN; PHYSICAL CHEMISTRY; PREDICTION; BIOAVAILABILITY; DIFFUSION; FOOD; INTESTINE ABSORPTION; LIPID METABOLISM; NON-PROGRAMMATIC; PHARMACOKINETICS; PHYSIOLOGY; REVIEW; SOLUBILITY;

ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL AVAILABILITY; CARRIER PROTEINS; DIFFUSION; FOOD; INTESTINAL ABSORPTION; LIPIDS; P-GLYCOPROTEIN; PHARMACOKINETICS; SOLUBILITY; LIPID METABOLISM; SYMPORTERS;

NON-PROGRAMMATIC;

EID: 0036000312     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00970002042006005     Document Type: Article

References (151)

1. Prescribability and switchability of highly variable drugs and drug products
2. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability
3. Surface activity concentration dependent intestinal permeability in the rat
4. Modern bioavailability, bioequivalence and biopharmaceutics classification system: New scientific approaches to international regulatory standards
5. Quantitative structure-pharmacokinetic relationships and drug design
6. Meal composition effects on the oral bioavailability of indinavir in HIV-infected patients
7. Drug, meal and formulation interactions influencing drug absorption after oral administration
8. Solutions and phase equilibria
9. Prediction of membrane permeability to peptides from calculated dynamic molecular surface properties
10. Solubility parameter and oral absorption
11. Predicting human oral bioavailability of a compound: Development of a novel quantitative structure-bioavailability relationship
12. A computer perspective of membranes: Molecular dynamics studies of lipid bilayer systems
13. Correlation of drug absorption with molecular surface properties
14. The influence of intestinal mucous components on the diffusion of drugs
15. Virtual screening of intestinal drug permeability
16. Intestinal absorption barriers and transport mechanisms, including secretory transport, for a cyclic peptide, fibrinogen antagonist
17. Effect of molecular charge on intestinal epithelial drug transport
18. Does fluid flow across the intestinal mucosa affect quantitative oral drug absorption? Is it time for a reevaluation?
19. Drug transport across gastrointestinal epithelia
20. Species differences in size discrimination in the paracellular pathway reflected by oral bioavailability of poly(ethylene glycol) and D-peptides
21. Transport approaches to the biopharmaceutical design of oral drug delivery systems: Prediction of intestinal absorption
22. Risedronate gastrointestinal absorption is independent of site and rate of administration
23. Reduced systemic availability of an antiarrhythmic drug, bidisomide, with meal co-administration: Relationship with region-dependent intestinal absorption
24. On the heterogeneity of drug dissolution and release
25. An integrated model for determining causes of poor oral drug absorption
26. Effect of change in shape factor of a single crystal on its dissolution behavior
27. Influence of crystal habit on trimethoprim suspension formulation
28. Gastrointestinal transit of nondisintegrating, nonerodible oral dosage forms in pigs
29. Physiological aspects of the design of dissolution tests
30. Evaluation of in vitro release rate and in vivo absorption characteristics of four metoprolol tartrate immediate-release tablet formulations
31. Identification of formulation and manufacturing variables that influence in vitro dissolution and in vivo bioavailability of propranolol hydrochloride tablets
32. The impact of formulation and process changes on in vitro dissolution and bioequivalence of piroxicam capsules
33. Setting bioequivalence requirements for drug development based on preclinical data: Optimizing oral drug delivery systems
34. Is the role of the small intestine in first-pass metabolism overemphasized?
35. Applications and limitations of interspecies scaling and in-vitro extrapolation in pharmacokinetics
36. Single-dose pharmacokinetics of indinavir and the effect of food
37. Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption: Theoretical approach
38. Effect of dexamethasone on the intestinal first-pass metabolism of indinavir in rats: Evidence of cytochrome P-450 A and P-glycoprotein induction
39. Metabolism of drugs and other xenobiotics in the gut lumen and wall
40. Extrahepatic metabolism of drugs in humans
41. Small intestinal cytochromes P450
42. First-pass metabolism of midazolam by the human intestine
43. Low bioavailability of amoxicillin in rats as a consequence of presystemic degradation in the intestine
44. Disposition of intravenous and oral cyclosporin after administration with grapefruit juice
45. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery
46. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics
47. Pharmacokinetics of chloramphenicol in domesticated animals
48. Studies on the role of intestinal bacteria in metabolism of synthetic and natural steroid hormones
49. Influence of D-glucose-induced water absorption on rat jejunal uptake of two passively absorbed drugs
50. Pharmacogenomics: The promise of personalized medicine
51. Physiological and pathophysiological regulation of cytochrome P450
52. Oral drug delivery technology: Addressing the solubility/permeability paradigm
53. The biopharmaceutics classification system (BCS): Class III drugs-better candidates for BA/BE waiver?
54. In vitro-in vivo relationship of several "immediate release" tablets containing a low permeability drug
55. The effect of mannitol on the oral bioavailability of cimetidine
56. Effect of sodium acid pyrophosphate on ranitidine bioavailability and gastrointestinal transit time
57. Effect of surfactants on albendazole absorption
58. Reversal of multidrug resistance by surfactants
59. Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80
60. Drug-excipient interactions
61. Studies of beneficial interactions between active medicaments and excipients in pharmaceutical formulations
62. Review: Quality and functionality of excipients
63. Interaction between bile salts and beta-adrenergic receptor antagonists
64. The influence of the interdigestive migrating myoelectric complex on the gastric emptying of liquids
65. Migrating electrical spike activity in the fasting human small intestine
66. The interdigestive myoelectric complex of the stomach and small bowel of dogs
67. Cyclic motor activity: Migrating motor complex
68. Effect of food on bioavailability of drugs
69. Paracellular drug transport across intestinal epithelia: Influence of charge and induced water efflux
70. Permeability of the rat small intestinal epithelium along villus-crypt axis: Effects of glucose transport
71. 51Cr-EDTA in cat small intestine in vivo
72. Effect of hydroxypropylmethylcellulose on gastrointestinal transit and luminal viscosity in dogs
73. Drug marker absorption in relation to pellet size, gastric motility and viscous meals in humans
74. The effects of diet, aging and disease-states on presystemic elimination and oral drug bioavailability in humans
75. Mechanisms and variations in the food effect on propranolol bioavailability
76. Influence of food and fluid ingestion on aspirin bioavailability
77. pH-related changes in the absorption of dipyridamole in the elderly
78. Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole
79. In vitro and in vivo evaluation in dogs and pigs of a hydrophilic matrix containing propylthiouracil
80. Geography of intestinal permeability and absorption
81. Heterogeneous tube model for the study of small intestinal transit flow
82. Gastrointestinal drug absorption: Is it time to consider heterogeneity as well as homogeneity?
83. Biology of membrane transport protein
84. The multidrug resistance protein family
85. Membrane transporters
86. Role of transport proteins in drug absorption, distribution and excretion
87. Human membrane transporter database: A Web-accessible relational database for drug transport studies and pharmacogenomics
88. Intestinal peptide transport system and oral drug availability
89. Drug transport and targeting
90. Multiplicity of the H+-dependent transport mechanism of dipeptide and anionicbeta-lactam antibiotic ceftibuten in rat intestinal brush-border membrane
91. The pathophysiology of diarrhea
92. The secretory intestinal transport of some beta-lactams antibiotics and anionic compounds: A mechanism contributing to poor drug absorption
93. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine
94. Intestinal drug efflux: Formulation and food effects
95. Expression and protein kinase C-dependent regulation of peptide/H 1 co-transport system in the Caco-2 human colon carcinoma cell line
96. Inhibition of the H+/peptide cotransporter in the human intestinal cell line Caco-2 by cyclic AMP
97. A rapid screening system to determine drug affinities for the intestinal dipeptide transporter 2: Affinities of ACE inhibitors
98. Structural basis for recognition of dipeptides by peptide transporters
99. Determination of intrinsic membrane transport parameters from perfused intestine experiments: A boundary layer approach to estimating the aqueous and unbiased membrane permeabilities
100. Neural modulation of cephalexin intestinal absorption through the di- and tripeptide brush border transporter of rat jejunum in vivo
101. Alpha(2)-adrenergic receptors stimulate oligopeptide transport in a human intestinal cell line
102. Heterotrimeric G proteins, vesicle trafficking, and CFTR Cl 2 channels
103. A heterotrimeric G protein of the Gi family is required for cAMP-triggered trafficking of aquaporin 2 in kidney epithelial cells
104. 3 H]RX821002 and distribution along the villus-crypt axis
105. Characterization and distribution of alpha2-adrenergic receptors in the human intestinal mucosa
106. Immuno-localization of H+/peptide cotransporter in rat digestive tract
107. Mechanism of intestinal absorption. Effect of clonidine on rabbit ileal villus and crypt cells
108. The xyz of ABC transporters
109. Analysis of the structure and expression pattern of MRP7 (ABCC10), a new member of the MRP subfamily
110. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells
111. Drug exsorption from blood into the gastrointestinal tract
112. Intestinal MDR transport proteins and P450 enzyme as barriers to oral drug delivery
113. The MDR1, C3435T polymorphism: Effects on P-glycoprotein expression/function and clinical consequences
114. Restricted intestinal absorption of some beta-lactam antibiotics by an energy-dependent efflux system in rat intestine
115. The barrier function of CYP3A4 and P-glycoprotein in the small bowel
116. Relevance of P-glycoprotein for the enteral absorption of cyclosporin A: In-vitro-in-vivo correlation
117. Repacking of the transmembrane domains of P-glycoprotein during the transport ATPase cycle
118. Communication between multiple drug binding sites on P-glycoprotein
119. Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine
120. Structure-activity relationship of P-glycoprotein substrates and modifiers
121. The drug efflux metabolism alliance: Biochemical aspects
122. Grapefruit juice increases felodipine oral availability in humans by decreasing CYP 3A protein expression
123. 1-adrenoceptor antagonist talinolol in man
124. Celprolol: An updated review of its pharmacokinetic properties and therapeutic efficacy in cardiovascular diseases
125. Biochemistry of multidrug resistance mediated by the multidrug transporter
126. Reversal of multidrug resistance phenotype by surfactants: Relationship to membrane lipid fluidity
127. Modulation of P-glycoprotein and expression by cytochrome P450 3A inducers in male and female rat livers
128. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
129. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
130. Effects of sodium deoxycholate and sodium caprate on the transport of epirubicin in human intestinal epithelial Caco2 cell layers and everted gut sacs of rats
131. Non-ionic detergent Tween 80 modulates VP-16 resistance in classical multidrug resistant K562 cells via enhancement of VP-16 influx
132. Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs
133. The effect of water-soluble vitamin E on cyclosporin pharmacokinetics in healthy volunteers
134. Lipid fluidity directly modulates the overall protein rotational mobility of the Ca-ATPase in sarcoplamsic reticulum
135. Resistance modulation in CHO cells by R-verapamil and bile salts is associated with physical and chemical changes in the cell membrane
136. Membrane fluidization by ether, other anesthetics, and certain agents abolishes P-glycoprotein ATPase activity and modulate efflux from multidrug-resistant cells
137. Reversal of multidrug resistance and increase in plasma membrane fluidity in CHO cells with R-verapamil and bile salts
138. Apical uptake of organic cations by human intestinal Caco-2 cells: Putative involvement of ASF transporters
139. Intestinal lipid absorption and transport
140. Gut expression and regulation of FAT/CD36: Possible role in fatty acid transport in rat enterocytes
141. A dual, concentration-dependent absorption mechanism of linoleic acid by rat jejunum in vitro
142. From interaction of lipidic vehicles with intestinal epithelial cell membranes to the formation and secretion of chylomicrons
143. Dietary cholesterol absorption: More than just bile
144. Uptake of cholesterol by small intestinal brush border membrane is protein-mediated
145. Intestinal absorption of triglyceride and cholesterol: Dietary and pharmacological inhibition to reduce cardiovascular risk
146. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters